Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 4, 2012, Pages 278-289

  Miller, Valerie L ^a   Lin, Hsueh Kung ^a,b   Murugan, Paari ^a   Fan, Michael ^c   Penning, Trevor M ^d   Brame, Lacy S ^e   Yang, Qing ^a   Fung, Kar Ming ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Adenocarcinoma; AKR1C3; Esophagus; Gastroesophageal junction; Lung; Non small cell carcinoma; Small cell carcinoma; Squamous cell carcinoma; Stomach

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ENZYMOLOGY; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; UNITED STATES;

3-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; OKLAHOMA; PREDICTIVE VALUE OF TESTS; SMALL CELL LUNG CARCINOMA; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864298385     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Jez JM, Flynn TG and Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997; 54 639-647.
2. Khanna M, Qin KN, Wang RW and Cheng KC. Substrate specificity, gene structure, and tissue -specific distribution of multiple human 3ahydroxysteroid dehydrogenases. J Biol Chem 1995; 270: 20162-20168.
3. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA and Penning TM. Expression and characterization of recombinant type 2 3a-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997; 11: 1971-1984.
4. Lin HK, Steckelbroeck S, Fung KM, Jones AN and Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/ type 5 17b-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004; 69: 795-801.
5. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM and Lin HK. Increased expression of type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13: 169-180.
6. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K. Human 3a-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldoketo reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351: 67-77.
7. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M and Sakai S. Identification of a principal mRNA species for human 3ahydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem (Tokyo) 1998; 124: 940-946.
8. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR and Penning TM. Human type 3 3a -hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 2003; 144: 2922-2932.
9. Byrns MC, Duan L, Lee SH, Blair IA and Penning TM. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol 2010; 118: 177-187.
10. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK. Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248:182-191.
11. Rizner TL, Smuc T, Rupreht R, Sinkovec J and Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006; 248:126-135.
12. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM and Fung KM. Suppressed expression of type 2 3a/type 5 17bhydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol 2010; 3: 608-617.
13. Ashley RA, Yu Z, Fung KM, Frimberger D, Kropp BP, Penning TM and Lin HK. Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology 2010; 76:67-72.
14. Lewis MJ, Wiebe JP and Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004; 4: 27.
15. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N and Sasano H. 17bhydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006; 248: 136-140.
16. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12:101-107.
17. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006; 66: 2815-2825.
18. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T and Naito M. Expression of androgen receptor through androgenconverting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61: 448-454.
19. Azzarello J, Fung KM and Lin HK. Tissue distribution of human AKR1C3 and rat homolog in adult genitourinary system. J Histochem Cytochem 2008; 56: 853-861.
20. Park AL, Lin HK, Yang Q, Sing CW, Fan M, Mapstone TB, Gross NL, Gumerlock MK, Martin MD, Rabb CH and Fung KM. Differential expression of type 2 3a/type 5 17b-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int J Clin Exp Pathol 2010; 3:743-754.
21. Azzarello JT, Lin HK, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung KM. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, andWilms' tumor. Int J Clin Exp Pathol 2009; 3:147-155.
22. Penning TM, Burczynski ME, Hung CF, McCoull KD, Palackal NT and Tsuruda LS. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chem Res Toxicol 1999; 12: 1-18.
23. Smithgall TE, Harvey RG and Penning TM. Regio- and stereospecificity of homogeneous 3ahydroxysteroid-dihydrodiol dehydrogenase for trans-dihydrodiol metabolites of polycyclic aromatic hydrocarbons. J Biol Chem 1986; 261: 6184-6191.
24. Hsu NY, Ho HC, Chow KC, Lin TY, Shih CS, Wang LS and Tsai CM. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of nonsmall cell lung cancer. Cancer Res 2001; 61:2727-2731.
25. Chen CY, Hsu CP, Hsu NY, Shih CS, Lin TY and Chow KC. Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer. Oncol Rep 2002; 9: 515-519.
26. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012; 25 Suppl 1: S18-30.
27. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS and Jagirdar J. Napsin a, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012; 136: 163-171.
28. Seike K, Murata M, Hirakawa K, Deyashiki Y and Kawanishi S. Oxidative DNA damage induced by benz[a]anthracene dihydrodiols in the presence of dihydrodiol dehydrogenase. Chem Res Toxicol 2004; 17: 1445-1451.
29. Xue W, Warshawsky D. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. Toxicol Appl Pharmacol 2005; 206: 73-93.
30. Cheng YW, Tsai HJ, Wu JY, Hsu YF, Chen CY, Hao NJ and Lee H. A possible role for dihydrodiol dehydrogenase in the formation of benzo[a]pyrene-DNA adducts in lung cancer cells and tumor tissues. Environ Mol Mutagen 2007; 48: 14-21.
31. Burczynski ME, Lin HK and Penning TM. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 1999; 59: 607-614.
32. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N and Rothman N. Oxidative damagerelated genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004; 25: 2177-2181.
33. Palackal NT, Lee SH, Harvey RG, Blair IA and Penning TM. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 2002; 277: 24799-24808.
34. Hung JJ, Chow KC, Wang HW and Wang LS. Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. Anticancer Res 2006; 26: 2949-2955.
35. Ax W, Soldan M, Koch L and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000; 59: 293-300.
36. Deng HB, Adikari M, Parekh HK and Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germcell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol 2004; 54: 301-307.
37. Deng HB, Parekh HK, Chow KC and Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 2002; 277: 15035-15043.
38. Chen J, Adikari M, Pallai R, Parekh HK and Simpkins H. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2008; 61: 979-987.
39. Chow KC, Lu MP and Wu MT. Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J Dermatol Sci 2006; 41: 205-212.
40. Tew KD, O'Brien M, Laing NM and Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact 1998; 111-112: 199-211.
41. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, Maggi A, Warner M, Gustafsson JA and Nord M. Regulation of postnatal lung development and homeostasis by estrogen receptor b. Mol Cell Biol 2003; 23: 8542-8552.
42. Spivack SD, Hurteau GJ, Fasco MJ and Kaminsky LS. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 2003; 9: 6002-6011.
43. Wu CT, Chang YL, Shih JY and Lee YC. The significance of estrogen receptor b in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005; 130: 979-986.
44. Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, Horvath S, Chia D, Garon E, Goodglick L and Pietras RJ. Progesteroneand estrogen receptor expression and activity in human non-small cell lung cancer. Steroids 2011; 76: 910-920.
45. Slatore CG, Chien JW, Au DH, Satia JA and White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010; 28: 1540-1546.